Indeed, it has been shown that within two years of anti-VEGF-A treatment, approximately 20–72% of patients with ocular neovascular diseases developed geographic atrophy (GA)12, 13, 14, 15, 16. The gene discussed is VEGFA; the disease is atrophic macular degeneration.